SUSTANON

TESTOSTERONE PROPIONATE 30mg
TESTOSTERONE PHENYL PROPIONATE 60mg
TESTOSTERONE ISOCAPROATE 60mg
TESTOSTERONE DECANOATE BP 100mg

Oil Base q.s.
Presented as box with 10 ml vial (multidose)

DESCRIPTION

Sustanon is used to treat for testosterone replacement
therapy in male hypogonadal disorders. It is an oil-based injectable containing four different testosterone esters: testosterone propionate (30 mg); testosterone phenyl propionate (60 mg); testosterone isocaproate (60mg); and testosterone decanoate (100 mg). It is an intelligently “engineered" blend designed to provide fast, yet extended release of testosterone. Thus, it can provide significant gains in strength and muscle tissue, as well as a noticeable increase in libido. The propionate and phenyl propionate esters in this product are quickly utilized, releasing into circulation within the first four days. The remaining esters are much slower to release, staying active in the body for approximately two and three weeks. It has a strong anabolic activity, with a pronounced androgenic component.

INDICATIONS

Sustanon Injection is indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone.

CONTRAINDICATIONS

Not intended for use in children. Known or suspected prostatic carcinoma and mammary carcinoma in the male. Not intended for use in female patients other than those with disseminated breast cancer.
Contraindicated in nephrosis or the nephrotic phase of nephritis, cardiac and renal failure, hypercalcaemia, oedema, jaundice, liver disease with impaired bilirubin excretion, testicular and hepatic carcinoma.

DOSAGE AND DIRECTIONS FOR USE

In males with delayed puberty: Various dosage regimens have been used; some call for lower dosages initially with gradual increases as puberty progresses, with or without a decrease to maintenance levels. Other regimens call for higher dosage to induce pubertal changes and lower dosage for maintenance after puberty. The chronological and skeletal ages must be taken into consideration, both in determining the initial dose and in adjusting the dose.
Dosage is within the range of 50 to 200 mg every 2 to 4 weeks for a limited duration, for example, 4 to 6 months. X-rays should be taken at appropriate intervals to determine the amount of bone maturation and skeletal development.
Palliation of inoperable mammary cancer in woman: A dosage of 200 to 400 mg every 2 to 4 weeks is recommended. Women with metastatic breast carcinoma must be followed closely because androgen therapy occasionally appears to accelerate the disease.

SIDE EFFECTS AND SPECIAL PRECAUTIONS

General: Women should be observed for signs of virilization. Because androgens may alter serum cholesterol concentration, caution should be used when administering these drugs to patients with a history of myocardial infarction or coronary artery disease. All patients: Any nausea, vomiting, changes in skin color or ankle swelling.

DRUG INTERACTIONS

When administered concurrently, the following drugs may interact with androgens, such as methandienone, have been reported to decrease the anticoagulant requirement. Patients receiving oral anticoagulant therapy require close monitoring especially when androgens are started or stopped.
Antidiabetic agents, oral or insulin. Cyclosporine Hepatotoxic medications, other human growth hormone (somatrem or somatropin).

PRESENTATION

250 mg/ml, 1 x 10 ml vial

STORAGE

Store in a cool dry place (30 °C E 2 °C). Protect from light.

Warming and rotating the ampoule between the palms of the hands will redissolve any crystals that may have been formed during storage at low temperatures